Effect of dose and dosage interval on the oral bioavailability of docetaxel in combination with a curcumin self-emulsifying drug delivery system (SEDDS)

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 37, Issue 3, 2012, Pages 217-224

  Yan, Yi Dong ^a   Marasini, Nirmal ^a   Choi, Young Keun ^a,b   Kim, Jong Oh ^a   Woo, Jong Soo ^b   Yong, Chul Soon ^a   Choi, Han Gon ^a,c  

^a Yeungnam University   (South Korea)

^b Hanmi Pharmaceutical Co Ltd   (South Korea)

^c Hanyang University   (South Korea)

Author keywords

Bioavailability; Curcumin; Docetaxel; Pharmacokinetics; SEDDS

Indexed keywords

CURCUMIN; DOCETAXEL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG POTENTIATION; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; RAT; SELF EMULSIFYING DRUG DELIVERY SYSTEM; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CURCUMIN; DRUG DELIVERY SYSTEMS; EMULSIONS; MALE; RATS; RATS, SPRAGUE-DAWLEY; TAXOIDS;

EID: 84871341605     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-011-0078-1     Document Type: Article

References (36)

1. Amit AK, Vandana BP (2008) Design and evaluation of selfemulsifying drug delivery systems (SEDDS) of nimodipine. AAPS PharmSciTech 9:191-196
2. Anuchapreeda S, Leechanachai P, Smith MM, Ambudkar SV, Limtrakul PN (2002) Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem Pharmacol 64:573-582
3. Bissery MC, Guenard D, Gueritte-Voegelein F, Lavelle F (1991) Experimental antitumour activity of Taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 51:4845-4852
4. Breedveld P, Beijnen JH, Schellens JH (2006) Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci 27:17-24
5. Fisher GA, Sikic BI (1995) Clinical studies with modulators of multidrug resistance. Hematol Oncol Clin North Am 9:363-382
6. Fracasso PM, Goldstein LJ, de Alwis DP, Rader JS, Arquette MA, Goodner SA, Wright LP, Fears CL, Gazak RJ, Andre VA, Burgess MF, Slapak CA, Schellens JH (2004) Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies. Clin Cancer Res 10:7220-7228
7. Gelderblom H, Verweij J, Nooter K, Sparreboom A (2001) Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37:1570-1598
8. Gershanik T, Benita S (2000) Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs. Eur J Pharm Biopharm 50:179-188
9. Gottesman MM, Pastan I (1989) Clinical trials of agents that reverse multidrug resistance. J Clin Oncol 7:409-411
10. Gueritte-Voegelin F, Guenard D, Lavelle F, Legoff MT, Mangatal L, Poiter P (1991) Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem 34:992-998
11. Hanauske AR, Degen D, Hilsenbeck SG, Bissery MC, Von Hoff DD (1992) Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumour cells. Anti-Cancer Drugs 3:121-124
12. Herwaarden AE, Wagenaar E, Kruijssen CMM, Waterschoot RAB, Smit JW, Song JY, Valk MA, Tellingen O, Hoorn JWA, Rosing H, Heijnen JH, Schinkel AH (2007) Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest 117:3583-3592
13. Horwitz SB (1992) Mechanism of action of taxol. Trends Pharmacol Sci 13:134-136
14. Kemper EM, Verheij M, Boogerd W, Beijnen JH, van Tellingen O (2004) Improved penetration of docetaxel into the brain by coadministration of inhibitors of P-glycoprotein. Eur J Cancer 40:1269-1274
15. Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Armaiz- Pena GN, Kamat AA, Spannuth WA, Gershenson DM, Lutgendorf SK, Aggarwal BB, Sood AK (2007) Curcumin inhibits tumour growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res 13:3423-3430
16. Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, Watkins PB (1994) Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab Dispos 22:947-955
17. Malingré MM, Richel DJ, Beijnen JH, Hilde R, Franciska J, Koopman WW, Ten BH, Margaret ES, Jan HMS (2001) Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J Clin Oncol 19:1160-1166
18. Marre F, Sanderink GJ, de Sousa G, Gaillard C, Martinet M, Rahmani R (1996) Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 56:1296-1302
19. Oostendorp RL, Huitema A, Rosing H, Jansen RS, Ter Heine R, Keessen M, Beijnen JH, Schellens JH (2009) Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumours. Clin Cancer Res 15:4228-4233
20. Ozols RF, Cunnion RE, Klecker W, Hamilton TC, Ostchega Y, Parrillo JE, Young RC (1987) Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 5:641-647
21. Patel D, Sawant KK (2009) Self micro-emulsifying drug delivery system: formulation development and biopharmaceutical evaluation of lipophilic drugs. Curr Drug Deliv 6:419-424
22. Pouton CW (1997) Formulation of self-emulsifying drug delivery systems. Adv Drug Deliv Rev 25:47-58
23. Ringel I, Horwitz SB (1991) Studies with RP56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 83:288-291
24. Romiti N, Tongiani R, Cervelli F, Chieli E (1998) Effects of curcumin on P-glycoprotein in primary cultures of rat hepatocytes. Life Sci 62:2349-2358
25. Shou M, Martinet M, Korzekwa KR, Krausz KW, Gonzalez FJ, Gelboin HV (1998) Role of human cytochrome P450 3A4 and 3A5 in the metabolism of Taxotere and its derivatives: Enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 8:391-401
26. Sinko PJ, Kunta JR, Usansky HH, Perry BA (2004) Differentiation of gut and hepatic first pass metabolism and secretion of saquinavir in ported rabbits. J Pharmacol Exp Ther 310:359-366
27. Society of Toxicology (SOT) (2009) Guiding principles in the use of animals in toxicology. http://www.toxicology.org/AI/FA/guidingprinciples.pdf
28. Songyot A, Pranee L, Melissa MS, Suresh VA, Porn-ngarm L (2002) Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem Pharmacol 64:573-582
29. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, Borst P, Nooijen WJ, Beijnen JH, van Tellingen O (1997) Limited oral bioavailability and active epithelial secretion of paclitaxel caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94:2031-2035
30. Valentine SP, LeNedelec MJ, Menzies AR, Scandlyn MJ, Goodin MG, Rosengren RJ (2006) Curcumin modulates drug metabolizing enzymes in the female Swiss Webster mouse. Life Sci 78:2391-2398
31. Wils P, Phung-Ba V, Warnery A, Lechardeur D, Raeissi S, Hidalgo IJ, Scherman D (1994) Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem Pharmacol 48:1528-1530
32. Woo JS, Lee CH, Shim CK, Hwang SJ (2003) Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031. Pharm Res 20:24-30
33. Yan YD, Kim DH, Sung JH, Yong CS, Choi HG (2010) Enhanced oral bioavailability of docetaxel in rats by four consecutive days of pre-treatment with curcumin. Int J Pharm 399:116-120
34. Yan YD, Kim JA, Kwak MK, Yoo BK, Yong CS, Choi HG (2011) Enhanced oral bioavailability of curcumin via a solid lipid-based self-emulsifying drug delivery system (SEDDS) using a spraydrying technique. Biol Pharm Bull 34:1179-1186
35. Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG (2002) Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther 303:323-332
36. Zhang W, Tan TMC, Lim LY (2007) Impact of curcumin-induced changed in P-glycoprotein and CYP3A expression on the phamacokinetics of peroral celiprolol and midazolam in rats. Drug Metab Dispos 35:110-115